What Is Beauvericin? Definition and What Research Reports

Definition

Beauvericin is a naturally occurring cyclic hexadepsipeptide: a closed ring made of six alternating units — three N-methyl-phenylalanine residues and three D-hydroxyisovaleric acid residues — joined by a mixture of amide (peptide) and ester (depsi) bonds. It is produced as a secondary metabolite by filamentous fungi, most notably the entomopathogenic fungus Beauveria bassiana (from which it takes its name), various Fusarium species, and Isaria species. Because the ring alternates peptide and ester linkages, beauvericin belongs structurally to the same family as the enniatins and shares their defining functional property: it behaves as an ionophore, complexing cations such as potassium, sodium and calcium and ferrying them across lipid membranes. In the scientific literature it is classified as an emerging mycotoxin and a food and feed contaminant — not as a therapeutic peptide, supplement or research peptide in the sense that term is used for synthetic analogues of human hormones.

Where the Term Comes From and How It Is Used

The word appears in three fairly distinct literatures, which is why definitions can look inconsistent at first glance:

• Food safety and toxicology. Here beauvericin is discussed as a Fusarium-derived contaminant of cereals, grain products and animal-derived foods, studied for occurrence, exposure and cytotoxic mechanism.
• Natural-product chemistry. Here it is a depsipeptide scaffold of interest for its ionophore chemistry and its antimicrobial, insecticidal and antiproliferative activities in laboratory systems.
• Peptide nomenclature. Beauvericin is frequently cited as a textbook example of a cyclic depsipeptide when explaining how ester bonds, N-methylation and macrocyclisation change a peptide's rigidity, membrane permeability and resistance to proteases.

None of these usages describes an approved medicine. Beauvericin is not an approved drug in any jurisdiction and is handled in published work as a laboratory chemical and a contaminant of concern. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, exposure or treatment.

Structural Snapshot

What the Published Literature Reports

Reviews and general characterisation

A 2020 review in Environmental Toxicology and Pharmacology, titled "Beauvericin: The beauty and the beast," surveyed the compound's dual profile — its ionophoric and bioactive properties alongside its toxicological concerns as a Fusarium mycotoxin (PMID 32028178). That framing captures why the same molecule turns up in both food-contaminant registers and natural-product screening papers.

Occurrence in food

Researchers surveying raw and UHT cow's milk in Poland measured enniatins and beauvericin in milk samples, reporting on the detectability of these emerging Fusarium mycotoxins in a commonly consumed food matrix (PMID 37786432). Occurrence surveys of this kind are the basis on which exposure questions are framed in the food-safety literature.

Metabolism and pharmacokinetics

A 2022 study in Toxins examined the in vitro metabolism and in vivo pharmacokinetics of beauvericin, characterising how the compound was metabolised and how its concentrations behaved over time in an animal model (PMID 35878215). Work of this type addresses how much of an ingested depsipeptide survives first-pass handling — a question that matters for interpreting any cell-culture result.

Cellular toxicity findings

Several groups have reported cytotoxic effects in mammalian cells. In rat hepatocytes, researchers examined the role of Nrf2 nucleus translocation in beauvericin-induced cell damage, linking the oxidative-stress response pathway to the injury observed (PMID 35737028). A 2024 study in human astrocytes explored beauvericin's toxic effects and mechanisms and reported a protective role for N-acetylcysteine in that model (PMID 38670497). In a human lymphoblastoid Jurkat T-cell model, the study compared beauvericin and enniatin B effects on immune-cell viability and function (PMID 29530640). A 2025 reproductive-toxicology paper reported that beauvericin disrupted the G2/M transition and induced meiotic arrest during mouse oocyte maturation (PMID 40840853).

Antiproliferative and antimicrobial activity in laboratory models

The same cytotoxicity that drives toxicological concern has also been screened as anticancer activity in cell lines. Beauvericin isolated from Isaria sp. showed antiproliferative and antimigration activities on pancreatic cancer cells in a 2020 report (PMID 33050002). A 2023 Phytomedicine study reported in vitro anti-cancer effects attributed to inhibition of actin polymerisation and Src phosphorylation (PMID 36610128), and a separate 2023 paper reported that beauvericin suppressed proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting the TGFBR2 pathway in preclinical models (PMID 37781043). On the antimicrobial side, researchers examined beauvericin in combination with antibiotics against methicillin-resistant Staphylococcus aureus and Salmonella typhimurium (PMID 38615997). A separate line of work reported that beauvericin inhibited melanogenesis via cAMP/PKA/CREB and LXR-α/p38 MAPK-mediated pathways (PMID 30297846). All of these were laboratory and animal investigations, not clinical trials in people.

Adverse Findings: What Studies Report

The published adverse findings for beauvericin come from cell and animal models rather than human clinical data. Reported effects include hepatocyte damage associated with Nrf2 pathway signalling in rat liver cells (PMID 35737028), cytotoxicity in human astrocytes attenuated by N-acetylcysteine in the study's protective-agent arm (PMID 38670497), effects on a human lymphoblastoid Jurkat T-cell model shared with enniatin B (PMID 29530640), and meiotic arrest with disrupted G2/M transition during mouse oocyte maturation (PMID 40840853). The 2020 review placed these toxicological signals alongside the compound's bioactivity in its overall assessment (PMID 32028178). No human dosing studies appear among the verified literature summarised here, and no human safety threshold can be stated from it.

How Beauvericin Differs From "Research Peptides"

Readers often encounter beauvericin in peptide glossaries because it is a peptide-containing macrocycle, but it differs from the synthetic analogues usually grouped under that heading in three ways. First, its origin is fungal rather than synthetic or recombinant. Second, its ester bonds and N-methylation make it a depsipeptide rather than a conventional linear peptide, which changes how it interacts with membranes. Third, its primary context in the literature is contaminant toxicology and natural-product screening — it is not used as a human therapeutic, and the reported biological effects described above were measured in cells, tissues and animal models.

Key Takeaways

• Beauvericin is a fungal cyclic hexadepsipeptide with ionophore activity, classed as an emerging mycotoxin.
• It has been detected in food matrices including cow's milk in a Polish survey (PMID 37786432).
• Its metabolism and pharmacokinetics were characterised in vitro and in vivo in a 2022 Toxins study (PMID 35878215).
• Published cytotoxicity and antiproliferative findings come from cell lines and animal models, not human trials.
• There is no approved human use, and this entry is definitional only.

References

• Beauvericin: The beauty and the beast (Environmental Toxicology and Pharmacology, 2020)
• Study on In Vitro Metabolism and In Vivo Pharmacokinetics of Beauvericin (Toxins, 2022)
• Survey of the enniatins and beauvericin in raw and UHT cow's milk in Poland (Journal of Veterinary Research, 2023)
• Role of Nrf2 Nucleus Translocation in Beauvericin-Induced Cell Damage in Rat Hepatocytes (Toxins, 2022)
• Exploration of beauvericin's toxic effects and mechanisms in human astrocytes and N-acetylcysteine's protective role (Toxicon, 2024)
• Beauvericin and enniatin B effects on a human lymphoblastoid Jurkat T-cell model (Food and Chemical Toxicology, 2018)
• Beauvericin disrupts G2/M transition and induces meiotic arrest during mouse oocyte maturation (Reproductive Toxicology, 2025)
• Antiproliferative and Antimigration Activities of Beauvericin Isolated from Isaria sp. on Pancreatic Cancer Cells (Molecules, 2020)
• In vitro anti-cancer effects of beauvericin through inhibition of actin polymerization and Src phosphorylation (Phytomedicine, 2023)
• Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway (International Journal of Biological Sciences, 2023)
• Interaction of beauvericin in combination with antibiotics against methicillin-resistant Staphylococcus aureus and Salmonella typhimurium (Toxicon, 2024)
• Beauvericin inhibits melanogenesis by regulating cAMP/PKA/CREB and LXR-α/p38 MAPK-mediated pathways (Scientific Reports, 2018)